Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Role of RANKL in cancer development and metastasis
by
Okamoto Kazuo
in
Bone cancer
/ Bone resorption
/ Cytokines
/ Immune checkpoint inhibitors
/ Metastases
/ Metastasis
/ Multiple myeloma
/ NF-κB protein
/ Osteoclastogenesis
/ TRANCE protein
/ Tumor cells
/ Tumorigenesis
2021
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Role of RANKL in cancer development and metastasis
by
Okamoto Kazuo
in
Bone cancer
/ Bone resorption
/ Cytokines
/ Immune checkpoint inhibitors
/ Metastases
/ Metastasis
/ Multiple myeloma
/ NF-κB protein
/ Osteoclastogenesis
/ TRANCE protein
/ Tumor cells
/ Tumorigenesis
2021
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Role of RANKL in cancer development and metastasis
2021
Request Book From Autostore
and Choose the Collection Method
Overview
Bone metastasis involves tumor-induced osteoclast activation, resulting in skeletal tumor progression as well as skeletal disorders. Aberrant expression of receptor activator of NF-κB ligand (RANKL), an essential cytokine for osteoclast differentiation, induced by the metastatic tumor cells is responsible for the pathological bone resorption in bone metastasis. A fully human anti-RANKL neutralizing antibody has been developed to block osteoclast activation and is now used for the treatment of patients with bone metastasis and multiple myeloma. On the other hand, numerous studies have revealed that the RANKL/RANK system also contributes to primary tumorigenesis as well as metastasis through osteoclast-independent processes. Furthermore, emerging clinical and preclinical evidence has suggested anti-tumor immune effects of RANKL blockade when added to immune checkpoint inhibitor therapies. Study on the pleiotropic functions of RANKL in tumorigenesis and metastasis is now expanding beyond the bone field and has been established as one of the most important areas of “RANKL biology”.
Publisher
Springer Nature B.V
This website uses cookies to ensure you get the best experience on our website.